Cargando…

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model

Mostrar otras versiones (2)

No treatments exist to slow or halt Parkinson’s disease (PD) progression; however, inhibition of leucine-rich repeat kinase 2 (LRRK2) activity represents one of the most promising therapeutic strategies. Genetic ablation and pharmacological LRRK2 inhibition have demonstrated promise in blocking α-sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Hien Tran, John, Neena, Delic, Vedad, Ikeda-Lee, Karli, Kim, Aneeza, Weihofen, Andreas, Swayze, Eric E., Kordasiewicz, Holly B., West, Andrew B., Volpicelli-Daley, Laura A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573879/ https://www.ncbi.nlm.nih.gov/pubmed/28918051 http://dx.doi.org/10.1016/j.omtn.2017.08.002

Ejemplares similares

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
por: Cole, Tracy A., et al.
Publicado: (2021)

Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides
por: Reidenbach, Andrew G., et al.
Publicado: (2019)

An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement
por: Poplawski, Shane G., et al.
Publicado: (2020)

Antisense oligonucleotides extend survival of prion-infected mice
por: Raymond, Gregory J., et al.
Publicado: (2019)

A single-cell map of antisense oligonucleotide activity in the brain
por: Mortberg, Meredith A, et al.
Publicado: (2023)

The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration
por: Jafar-nejad, Paymaan, et al.
Publicado: (2020)

A single-cell map of antisense oligonucleotide activity in the brain
por: Mortberg, Meredith A, et al.
Publicado: (2023)

Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein
por: Brzozowski, Charlotte F., et al.
Publicado: (2021)

Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice
por: Korecka, Joanna A., et al.
Publicado: (2020)

Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
por: Østergaard, Michael E., et al.
Publicado: (2013)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain
por: Xu, Enquan, et al.
Publicado: (2022)

Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system
por: Sullivan, Jenna M., et al.
Publicado: (2020)

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models
por: Moore, Lauren R., et al.
Publicado: (2017)

Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
por: Skotte, Niels H., et al.
Publicado: (2014)

α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration
por: Harms, Ashley S., et al.
Publicado: (2017)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice
por: Chappell, Alfred E, et al.
Publicado: (2020)

Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment
por: O’Callaghan, Brennon, et al.
Publicado: (2020)

Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides
por: Østergaard, Michael E., et al.
Publicado: (2017)

Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
por: Prakash, Thazha P, et al.
Publicado: (2019)

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
por: Hua, Yimin, et al.
Publicado: (2007)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

Formation of templated inclusions in a forebrain α-synuclein mouse model is independent of LRRK2
por: Dues, Dylan J., et al.
Publicado: (2023)

Templated α-Synuclein Inclusion Formation Is Independent of Endogenous Tau
por: Stoyka, Lindsay E., et al.
Publicado: (2021)

miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
por: Suvarna, Vasanti, et al.
Publicado: (2022)

Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
por: Qiao, Yuanyuan, et al.
Publicado: (2023)

Initiation and propagation of α-synuclein aggregation in the nervous system
por: Hijaz, Baraa A., et al.
Publicado: (2020)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)

Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
por: Mummery, Catherine J., et al.
Publicado: (2023)

Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions
por: Stoyka, Lindsay E., et al.
Publicado: (2019)

Elucidation of the Biotransformation Pathways of a Galnac(3)-conjugated Antisense Oligonucleotide in Rats and Monkeys
por: Shemesh, Colby S, et al.
Publicado: (2016)

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation
por: Kawakami, Fumitaka, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5gkagko01rvoa3jm816oqfjv95